Compare VFF & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VFF | ACIU |
|---|---|---|
| Founded | 1989 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 230.2M | 244.3M |
| IPO Year | 2013 | 2015 |
| Metric | VFF | ACIU |
|---|---|---|
| Price | $2.03 | $2.34 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | ★ 1.2M | 295.7K |
| Earning Date | 05-11-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 184.38 | N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $215,937,000.00 | N/A |
| Revenue This Year | $12.19 | $706.75 |
| Revenue Next Year | $15.82 | $321.13 |
| P/E Ratio | $93.50 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.14 | $1.94 |
| 52 Week High | $4.99 | $4.00 |
| Indicator | VFF | ACIU |
|---|---|---|
| Relative Strength Index (RSI) | 42.37 | 42.10 |
| Support Level | N/A | N/A |
| Resistance Level | $3.66 | $3.92 |
| Average True Range (ATR) | 0.09 | 0.13 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 60.27 | 38.05 |
Village Farms International Inc owns and operates intensive agricultural greenhouse facilities in British Columbia and Texas, where it produces, markets and sells tomatoes, bell peppers and cucumbers. Its wholly owned subsidiary, Pure Sunfarms, is a vertically integrated licensed producer and supplier of cannabis products sold to other licensed providers and provincial governments across Canada and internationally. The Company's wholly owned subsidiary, Balanced Health, develops and sells, cannabidiol (CBD) based products including ingestible, edible and topical applications. The operating segments of the Company are VF Fresh (Produce), Cannabis Canada, Cannabis U.S., Clean Energy, and Cannabis - Netherlands. The company makes majority of its revenue from the Cannabis Canada segment.
AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.